Jeremy Hirota’s Post

View profile for Jeremy Hirota

Associate Professor - Medicine - McMaster University and Co-Founder and CSO at Tessella Biosciences

I think the quote is important about "chipping away at problems bit by bit". Bioprinting was overhyped 10 years ago - but the hard work is being done by groups led by Tamer Mohamed, Sam Wadsworth and Simon Beyer at Aspect Biosystems . Tessella Biosciences Inc. is working hard on high performance biomaterial inks for 3D printing with the goal of transitioning our R&D grade products to GMP for human use.

View profile for Kyle LaHucik

Biotech journalist @ Endpoints News

A Vancouver biotech working on bioprinted tissue therapeutics has reeled in $115 million via a Series B. The capital will support Aspect Biosystems' in-house programs in endocrine and metabolic disorders while also working on diabetes with partner Novo Nordisk. Nan Li, a managing partner at the round's lead investor Dimension and new Aspect board member, called it a “modality that’s too elegant to ignore.” “It’s one of these modalities that the industry continues to invest in because of its promise. We’re kind of chipping away at the problems bit by bit but even with some recent clinical challenges in regenerative medicine, a lot of large pharma companies continue to make bets there and put it on their 10-year roadmap for where they see the industry going,” Li told Endpoints News More below from my interviews with Aspect CEO Tamer Mohamed and Li: #aspectbiosystems #novonordisk #tissuetherapeutics #bioprintedtissue #metabolicdisorders #endocrinedisorders #biotechvc #biotechfunding #canadianbiotech

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

endpts.com

To view or add a comment, sign in

Explore topics